CSPC Pharmaceutical (HKG:1093) has obtained approval to conduct a clinical trial of Prusogliptin and Metformin Extended-Release Tablets from China's National Medical Products Administration, a Tuesday filing with the Hong Kong bourse said.
The indication for the trial approval is for use as an adjunct to diet and exercise in the treatment of adult patients with type 2 diabetes mellitus.
The product is the world's first fixed-dose combination formulation of prusogliptin and metformin hydrochloride approved for clinical trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.